ArticleTobacco control2018
Heated tobacco product regulation under US law and the FCTC.
Article in Tobacco control, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- PMI's heated tobacco products marketing claims of reduced risk and reduced exposure may entice youth to try and continue using these products.Tobacco control · 2020Trial
- Trends and transition dynamics of heated tobacco product use in Japan, 2015-2025: a repeated cross-sectional and longitudinal study.The Lancet regional health. Western Pacific · 2026Article
- Nationwide trends in cigarette, heated tobacco product, e-cigarette, and multiple-product use in Japan 2017-2025.PCN reports : psychiatry and clinical neurosciences · 2026Article
- The policy implementation playbook: a cross-policy taxonomy of post-adoption tobacco industry tactics.Globalization and health · 2026Review
- Nicotine consumption in Poland: from traditional cigarettes to modern products - a scoping review.BMC public health · 2025Article
- Is it about substituting an addiction with another? development and initial psychometric properties of the first heated tobacco products addiction questionnaire (HeaTPAQ).Addiction science & clinical practice · 2025Article
- Association between Tobacco Industry Interference Index (TIII) and MPOWER measures and adult daily smoking prevalence rate in 30 countries.Globalization and health · 2024Article
- Scanned information exposure and support for tobacco regulations among US youth and young adult tobacco product users and non-users.Health education research · 2023Article
- The spread of heated tobacco product (HTP) use across various subgroups during 2015-16 and 2017-18 in Japan.Environmental health and preventive medicine · 2023Article
- FDA's reduced exposure marketing order for IQOS: why it is not a reliable global model.Tobacco control · 2022Article
- Moving targets: how the rapidly changing tobacco and nicotine landscape creates advertising and promotion policy challenges.Tobacco control · 2022Review
- United States Food and Drug Administration's authorization of reduced exposure claims for IQOSRevista panamericana de salud publica = Pan American journal of public health · 2022Article
- Article
- Confronting the burden of tobacco-related lung cancer in Europe in the next decades.The Lancet regional health. Europe · 2021Article
- The Frequency of Use and Harm Perception of Heated Tobacco Products (HTPs): The 2019 Cross-Sectional Survey among Medical Students from Poland.International journal of environmental research and public health · 2021Article
- The FCTC dilemma on heated tobacco products.Globalization and health · 2020Article
- Analysis of FDA's IQOS marketing authorisation and its policy impacts.Tobacco control · 2020Article
- Reviewing the oral carcinogenic potential of E-cigarettes using the Bradford Hill criteria of causation.Translational cancer research · 2020Review
- Young Adult Correlates of IQOS Curiosity, Interest, and Likelihood of Use.Tobacco regulatory science · 2020Article
- Evolving IQOS packaging designs change perceptions of product appeal, uniqueness, quality and safety: a randomised experiment, 2018, USA.Tobacco control · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Tobacco companies are marketing new 'heated tobacco products' (HTPs) composed of battery-powered holders, chargers and tobacco plugs or sticks. The non-tobacco HTP components have escaped effective regulation under many countries' tobacco control laws because they are packaged and sold separately from the tobacco-containing components. In the USA, HTPs cannot be marketed unless the Food and Drug Administration determines that allowing their sale would be 'appropriate for the protection of the public health'. Philip Morris International (PMI) is seeking permission to market its IQOS HTP in the USA with 'modified risk tobacco product' (MRTP) claims that it reduces exposure to harmful substances and is less harmful than other tobacco products. However, PMI has not submitted adequate scientific evidence required by US law to demonstrate that the product is significantly less harmful to users than other tobacco products, that its labelling would not mislead consumers, or that its marketing-with or without MRTP claims-would benefit the health of the population as a whole. Parties to the WHO Framework Convention on Tobacco Control (FCTC) must take measures to reduce tobacco use and nicotine addiction, and prevent false or misleading tobacco product labelling, advertising and promotions; the introduction of new HTPs must be assessed according to these goals. All components of HTPs should be regulated at least as stringently as existing tobacco products, including restrictions on labelling, advertising, promotion and sponsorship, sales to minors, price and taxation policies and smokefree measures. There is nothing in US law or the FCTC that prevents authorities from prohibiting HTPs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.